Improvement in cadaveric renal transplant survival.
D000367:Age Factors; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001707:Biopsy, Needle; D001926:Brain Death; D002102:Cadaver; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects* / Q000528:radiation effects; D006649:Histocompatibility Antigens; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy; D007275:Injections, Intravenous; D016030:Kidney Transplantation; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011792:Quebec; D014180:Transplantation / Q000401:mortality; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D006649:Histocompatibility Antigens; D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone; D008775:Methylprednisolone